Quick answers
- What is Hydrocortisone butyrate used for?
- The FDA-approved label (Hydrocortisone Butyrate, Oceanside Pharmaceuticals, December 31, 2020) says: “Hydrocortisone Butyrate Ointment, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Hydrocortisone butyrate have a boxed warning?
- No. None of the 5 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Hydrocortisone butyrate?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Hydrocortisone butyrate been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Hydrocortisone butyrate?
- 6 companies list prescription products of Hydrocortisone butyrate in the FDA NDC Directory, including Sun Pharmaceutical Industries, Inc., Bryant Ranch Prepack and The J. Molner Company LLC.
What Hydrocortisone butyrate is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
Hydrocortisone Butyrate Ointment, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
— FDA label: Hydrocortisone Butyrate, Oceanside Pharmaceuticals, effective December 31, 2020. Read the full label on DailyMed →
The FDA has 5 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 5 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Lotion · Ointment · Solution · Cream |
|---|---|
| Route | Topical |
| Prescription products | 8 in the FDA NDC Directory |
| Brand names | Evesse |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| hydrocortisone butyrate 0.1% cream | Generic | $2.31–$2.50 per gram 2 packages, lowest to highest |
| hydrocortisone butyrate 0.1% ointment | Generic | $2.04–$2.18 per gram 2 packages, lowest to highest |
| hydrocortisone butyrate 1 mg/mL lotion | Generic | $0.6999 per mL |
| hydrocortisone butyrate 1 mg/mL solution | Generic | $2.05 per mL |
NADAC list of November 4, 2026; these prices took effect between July 22, 2026 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Sun Pharmaceutical Industries, Inc.3 products
- Bryant Ranch Prepack1 product
- The J. Molner Company LLC1 product
- Perfero Pharma, Inc.1 product
- Oceanside Pharmaceuticals1 product
- Lupin Pharmaceuticals, Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA018652 LOCOID | Precision Dermat | October 29, 1982 | 6, latest October 30, 2014 2014: Labeling · 2013: Manufacturing (CMC) · 1996: Manufacturing (CMC) |
Generic approvals (5)
- ANDA076364Taro Pharm Inds · January 14, 2004
- ANDA076842Taro · December 27, 2004
- ANDA076654Taro Pharm Inds · August 3, 2005
- ANDA209556The J Molner · November 21, 2017
- ANDA210209Lupin · August 17, 2018
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Hydrocortisone Butyrate, Oceanside Pharmaceuticals, effective December 31, 2020; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →